Jinling Pharmaceutical released its 2026 half-year report, showing first-half net profit attributable to the parent of 50.38 million yuan, up 4.2% year on year. Operating revenue was 1.584 billion yuan, down 1.04% year on year. Net profit attributable to the parent after deducting non-recurring items was 48.91 million yuan, up 37.7% year on year. Net operating cash flow was 247 million yuan, up 1,461.4% year on year. Earnings per share were 0.081 yuan. In the second quarter, operating revenue was 816 million yuan, up 3.1% year on year. Net profit attributable to the parent was 22.38 million yuan, down 11.7% year on year. Net profit attributable to the parent after deducting non-recurring items was 29.65 million yuan, up 96.7% year on year. As of the end of the second quarter, total assets were 5.992 billion yuan, down 0.2% from the end of the previous year. Net assets attributable to the parent were 3.766 billion yuan, down 0.3% from the end of the previous year. The company said its operating business did not undergo major changes during the reporting period. Its main businesses cover pharmaceutical and medical device manufacturing, medical rehabilitation and elderly care services, and other areas. Core products form a multi-category coordinated development matrix, and the medical rehabilitation and elderly care segment maintained stable operations.
Jinling Pharmaceutical Co LtdNet profit attributable to parent up 4.2% and after-deduction net profit up 37.7% year on year.
